Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.

De Sanctis, R; Bruzzi, P; Zambelli, A

Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.

De Sanctis, R; Bruzzi, P; Zambelli, A.

Afiliação

De Sanctis R; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan. Electronic address: rita.de_sanctis@hunimed.eu.
Bruzzi P; Department of Health Sciences, University of Genoa, Genova, Italy.
Zambelli A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan.

Ann Oncol ; 2024 Sep 03.

Article em En | MEDLINE | ID: mdl-39236982

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article